http://orcid.org/0000-0001-8816-1199
References
- Jett DA, Yeung DT. The CounterACT Research Network: basic mechanisms and practical applications. Proc Am Thorac Soc. 2010;7:254–256.
- Bebarta VS, Pitotti RL, Boudreau S, et al. Intraosseous versus intravenous infusion of hydroxocobalamin for the treatment of acute severe cyanide toxicity in a swine model. Acad Emerg Med. 2014;21:1203–1211.
- Bebarta VS, Pitotti RL, Dixon P, et al. Hydroxocobalamin versus sodium thiosulfate for the treatment of acute cyanide toxicity in a swine (Sus scrofa) model. Ann Emerg Med. 2012;59:532–539.
- Manandhar E, Maslamani N, Petrikovics I, et al. Determination of dimethyl trisulfide in rabbit blood using stir bar sorptive extraction gas chromatography-mass spectrometry. J Chromatogr A. 2016;1461:10–17.
- Petrikovics I, Cannon E, McGuinn W, et al. Cyanide antagonism with carrier erythrocytes and organic thiosulfonates. Toxicol Sci. 1995;24:86–93.
- Petrikovics I, Jayanna P, Childress J, et al. Optimization of liposomal lipid composition for a new, reactive sulfur donor, and in vivo efficacy studies on mice to antagonize cyanide intoxication. J Drug Deliv. 2011;2011:1.
- Kiss L, Bocsik A, Walter FR, et al. From the cover: in vitro and in vivo blood-brain barrier penetration studies with the novel cyanide antidote candidate dimethyl trisulfide in mice. Toxicol Sci. 2017;1;160:398–407.
- Rockwood GA, Thompson DE, Petrikovics I. Dimethyl trisulfide: a novel cyanide countermeasure. Toxicol Ind Health. 2016;32:2009–2016.
- Kovacs K, K, Jayanna P, Duke A, et al. A lipid base formulation for intramuscular administration of a novel sulfur donor for cyanide antagonism. Cdd. 2016;13:1351–1357.
- Kovacs K, Duke AC, Shifflet M, et al. Parenteral dosage form development and testing of dimethyl trisulfide, as an antidote candidate to combat cyanide intoxication. Pharm Dev Technol. 2017;22:958–963.
- DeLeon SM, Downey JD, Hildenberger DM, et al. DMTS is an effective treatment in both inhalation and injection models for cyanide poisoning using unanesthetized mice. Clin Toxicol. 2018;56:332–341.
- Bebarta VS, Tanen DA, Boudreau S, et al. Intravenous cobinamide versus hydroxocobalamin for acute treatment of severe cyanide poisoning in a swine (Sus scrofa) model. Ann Emerg Med. 2014;64:612–619.
- Lee J, Keuter KA, Kim J, et al. Noninvasive in vivo monitoring of cyanide toxicity and treatment using diffuse optical spectroscopy in a rabbit model. Mil Med. 2009;174:615–621.
- Reid FM, Jett DA, Platoff Jr., GE, et al. Animal Models for Testing Antidotes Against an Oral Cyanide Challenge. DTIC Report: DTIC: National Institutes of Health/National Institute of Neurological Disorders and Stroke, National Institutes of Health/National Institute of Allergy and Infectious Diseases, Battelle; Aug 2016 CBRNIAC-SS3-689.
- U.S. Department of Health and Human Services NIoH. NIH strategic plan and research agenda for medical countermeasures against chemical threats. National Institute of Health Bethesda: MD; 2007.
- Brenner M, Azer SM, Oh K-J, et al. Oral glycine and sodium thiosulfate for lethal cyanide ingestion. J Clin Toxicol 2017;7:355.
- Brenner M, Mahon SB, Lee J, et al. Comparison of cobinamide to hydroxocobalamin in reversing cyanide physiologic effects in rabbits using diffuse optical spectroscopy monitoring. J Biomed Opt. 2010;15:017001
- Food and Drug Administration Center for Drug Evaluation and Research. Product Development Under the Animal Rule Guidance for Industry Oct 2015. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm399217.pdf
- U.S. Department of Health and Human Services NIoH, PHEMCE. 2016 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan. 2016.